The Dadachanji Group announced the official launch of KAISHA Pharma. KAISHA Pharma is a new global pharmaceutical packaging company. It is backed by an initial investment of €45 million. The investment is part of a significant campaign, valued at multiple million euros, committed to infrastructure investments, increasing manufacturing capacity, and improving general operational efficiency.

KAISHA Pharma continues the legacy of pharmaceutical glass packaging established by the Dadachanji group, which has been active in the industry for nearly 35 years. The new entity is established for the benefit of pharmaceutical and biotechnology firms doing business in India and in various international markets.

Comprehensive product offerings and core emphasis

KAISHA Pharma provides a comprehensive spectrum of tubular glass product lines. It has a large base portfolio of primary products such as ampoules, vials, prefilled syringes, and cartridges. Beyond the aforementioned products, this company offers pre-engineered (Ready-to-Use or RTU) platforms designed to accommodate vial, pre-filled syringe, and cartridge packaging. 

They are designed to allow the conduct of safer, faster, and more efficient fill-finish processes while complying with the increasingly rigorous quality and safety standards demanded by international pharmaceutical companies.

In addition to packaging products, KAISHA Pharma is working on innovative specialty containment systems for high-value biologics, advanced therapeutics, and sensitive drug formulations. 

These customized containment solutions feature a robust focus on product integrity, chemical compatibility, and general performance. The company’s ability to handle complex formulations is designed to serve the specialized requirements of contemporary biotechnology and pharmaceutical firms from various regions.

Leadership vision and operational strategy

KAISHA Pharma is building an extensive manufacturing facility of over 300,000 square feet of manufacturing area to accommodate its operational strategy. This plant will include fully integrated production lines optimized for high-efficiency manufacturing. 

The infrastructure will include advanced camera inspection equipment for quality control and specialized laboratories comprising advanced analytical and testing equipment. This configuration assures that all manufactured parts conform to strict global quality requirements throughout the whole process.

KAISHA Pharma is building an International Business Development office in Europe along with its manufacturing base. It will operate as a hub of the business focused on customer engagement, technical cooperation, and continuous market expansion across the European region and the world.

KAIRUS Dadachanji, Managing Director of KAISHA Pharma, underlined that the experience is a defining moment in his professional career. Their mission is to build one of the most agile and technically capable ventures with an undeniable focus on customer success and becoming a completely global business, he explained. His promise is to employ decades of institutional knowledge with a simultaneous modernization of the company’s capabilities to remain competitive on a global scale.

Reinforcing that view, Rishad Dadachanji said the group has established the trust of customers, partners, and colleagues across the pharmaceutical sector over the years. He noted that KAISHA Pharma continues to build on that strong foundation and embraces the new challenge opportunities found as a result of evolving global markets. The collective knowledge and expertise of this group is the foundation upon which the company’s future expansion efforts and partnerships are built.

Conclusion

KAISHA Pharma is a major addition to the Dadachanji’s pharmaceutical packaging portfolio, with €45 million injected into the new company. The partnership brings together technical expertise and a range of advanced camera inspections, combined with more than 300,000 square feet of manufacturing expertise and dedicated testing laboratories.

KAISHA Pharma is supported by its international team in Europe, enabling pharmaceutical and biotechnology companies to access tubular glass packaging, Ready-to-Use platforms, and specialist containment solutions worldwide.